April 21st 2025
Teigen’s son was diagnosed with type 1 diabetes, inspiring her to promote the importance of early testing.
Non-Personal Promotion & Synchronized Storytelling: A Q&A with Matt Titus, CCO of Epocrates
May 2nd 2022Healthcare Providers (HCPs), also every day consumers of digital information, have not been satisfied with the level of engagement delivered by pharma in comparison to other industries. Pharm Exec chats with Matt Titus, CCO of Epocrates, about the key role Non-Personal Promotion (NPP) plays in an omnichannel approach.
MediPharm Labs Names Experienced Pharma and Med Tech Executive David Pidduck, as CEO
April 25th 2022Over the course of his career, Mr. Pidduck has been involved in the successful ground-up commercialization of several products in both Canadian and international markets and brings a track record of both organic execution as well as M&A and integration expertise.
Tackling Health Disparities and Inequities for Women with Heart Failure
April 25th 2022Boehringer Ingelheim and Lilly launch Hear Your Heart™, an empowering health initiative to provide resources and education for women with heart failure, especially Black and Latina women, to help optimize their care.
Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes Globally
April 25th 2022Bringing together Bristol Myers Squibb and Celgene on one clinical trial management system, company goes live with Vault CTMS in record speed. Modernization streamlines trial management to speed medicines to patients.
Miruna Sasu, Former Johnson & Johnson Executive, Takes the Helm at COTA, Inc. as President and CEO
March 24th 2022Pharma trailblazer will accelerate growth at COTA with a focus on advancing real-world data use in drug development, increasing diversity in clinical trials, and supporting the move to data-driven, value-based cancer care.
Insilico Medicine Announces Strategic Collaboration with EQRx
March 24th 2022The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices.